source
- Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP LossHow Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.onclive · 2mo ago↗ source
- Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast CancerBreast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.onclive · 2mo ago↗ source
- Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line StrategiesAparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.onclive · 2mo ago